COVID-19 ARDS is characterized by higher extravascular lung water than non-COVID-19 ARDS: the PiCCOVID study.
Hemodynamic monitoring
Mechanical ventilation
SARS-CoV-2
Transpulmonary thermodilution
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
received:
18
02
2021
accepted:
06
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
10
6
2021
Statut:
epublish
Résumé
In acute respiratory distress syndrome (ARDS), extravascular lung water index (EVLWi) and pulmonary vascular permeability index (PVPI) measured by transpulmonary thermodilution reflect the degree of lung injury. Whether EVLWi and PVPI are different between non-COVID-19 ARDS and the ARDS due to COVID-19 has never been reported. We aimed at comparing EVLWi, PVPI, respiratory mechanics and hemodynamics in patients with COVID-19 ARDS vs. ARDS of other origin. Between March and October 2020, in an observational study conducted in intensive care units from three university hospitals, 60 patients with COVID-19-related ARDS monitored by transpulmonary thermodilution were compared to the 60 consecutive non-COVID-19 ARDS admitted immediately before the COVID-19 outbreak between December 2018 and February 2020. Driving pressure was similar between patients with COVID-19 and non-COVID-19 ARDS, at baseline as well as during the study period. Compared to patients without COVID-19, those with COVID-19 exhibited higher EVLWi, both at the baseline (17 (14-21) vs. 15 (11-19) mL/kg, respectively, p = 0.03) and at the time of its maximal value (24 (18-27) vs. 21 (15-24) mL/kg, respectively, p = 0.01). Similar results were observed for PVPI. In COVID-19 patients, the worst ratio between arterial oxygen partial pressure over oxygen inspired fraction was lower (81 (70-109) vs. 100 (80-124) mmHg, respectively, p = 0.02) and prone positioning and extracorporeal membrane oxygenation (ECMO) were more frequently used than in patients without COVID-19. COVID-19 patients had lower maximal lactate level and maximal norepinephrine dose than patients without COVID-19. Day-60 mortality was similar between groups (57% vs. 65%, respectively, p = 0.45). The maximal value of EVLWi and PVPI remained independently associated with outcome in the whole cohort. Compared to ARDS patients without COVID-19, patients with COVID-19 had similar lung mechanics, but higher EVLWi and PVPI values from the beginning of the disease. This was associated with worse oxygenation and with more requirement of prone positioning and ECMO. This is compatible with the specific lung inflammation and severe diffuse alveolar damage related to COVID-19. By contrast, patients with COVID-19 had fewer hemodynamic derangement. Eventually, mortality was similar between groups. ClinicalTrials.gov (NCT04337983). Registered 30 March 2020-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04337983 .
Sections du résumé
BACKGROUND
In acute respiratory distress syndrome (ARDS), extravascular lung water index (EVLWi) and pulmonary vascular permeability index (PVPI) measured by transpulmonary thermodilution reflect the degree of lung injury. Whether EVLWi and PVPI are different between non-COVID-19 ARDS and the ARDS due to COVID-19 has never been reported. We aimed at comparing EVLWi, PVPI, respiratory mechanics and hemodynamics in patients with COVID-19 ARDS vs. ARDS of other origin.
METHODS
Between March and October 2020, in an observational study conducted in intensive care units from three university hospitals, 60 patients with COVID-19-related ARDS monitored by transpulmonary thermodilution were compared to the 60 consecutive non-COVID-19 ARDS admitted immediately before the COVID-19 outbreak between December 2018 and February 2020.
RESULTS
Driving pressure was similar between patients with COVID-19 and non-COVID-19 ARDS, at baseline as well as during the study period. Compared to patients without COVID-19, those with COVID-19 exhibited higher EVLWi, both at the baseline (17 (14-21) vs. 15 (11-19) mL/kg, respectively, p = 0.03) and at the time of its maximal value (24 (18-27) vs. 21 (15-24) mL/kg, respectively, p = 0.01). Similar results were observed for PVPI. In COVID-19 patients, the worst ratio between arterial oxygen partial pressure over oxygen inspired fraction was lower (81 (70-109) vs. 100 (80-124) mmHg, respectively, p = 0.02) and prone positioning and extracorporeal membrane oxygenation (ECMO) were more frequently used than in patients without COVID-19. COVID-19 patients had lower maximal lactate level and maximal norepinephrine dose than patients without COVID-19. Day-60 mortality was similar between groups (57% vs. 65%, respectively, p = 0.45). The maximal value of EVLWi and PVPI remained independently associated with outcome in the whole cohort.
CONCLUSION
Compared to ARDS patients without COVID-19, patients with COVID-19 had similar lung mechanics, but higher EVLWi and PVPI values from the beginning of the disease. This was associated with worse oxygenation and with more requirement of prone positioning and ECMO. This is compatible with the specific lung inflammation and severe diffuse alveolar damage related to COVID-19. By contrast, patients with COVID-19 had fewer hemodynamic derangement. Eventually, mortality was similar between groups.
TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION
ClinicalTrials.gov (NCT04337983). Registered 30 March 2020-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04337983 .
Identifiants
pubmed: 34074313
doi: 10.1186/s13054-021-03594-6
pii: 10.1186/s13054-021-03594-6
pmc: PMC8169440
doi:
Banques de données
ClinicalTrials.gov
['NCT04337983']
Types de publication
Clinical Trial
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
186Références
Ann Intensive Care. 2015 Dec;5(1):38
pubmed: 26546321
Lancet Respir Med. 2020 Dec;8(12):1201-1208
pubmed: 32861276
Intensive Care Med. 2020 Dec;46(12):2200-2211
pubmed: 32728965
Lancet Infect Dis. 2020 Oct;20(10):1135-1140
pubmed: 32526193
Virchows Arch. 2021 Mar;478(3):471-485
pubmed: 32989525
Am J Respir Crit Care Med. 2013 Apr 1;187(7):761-7
pubmed: 23370917
Intensive Care Med. 2006 Sep;32(9):1315-21
pubmed: 16741694
N Engl J Med. 2010 Sep 16;363(12):1107-16
pubmed: 20843245
Crit Care. 2017 Jun 19;21(1):147
pubmed: 28625165
Intensive Care Med. 2020 Aug;46(8):1651-1652
pubmed: 32468086
Am J Respir Crit Care Med. 2020 May 15;201(10):1299-1300
pubmed: 32228035
J Am Coll Cardiol. 2020 Aug 4;76(5):533-546
pubmed: 32517963
J Interv Card Electrophysiol. 2020 Nov;59(2):329-336
pubmed: 32494896
Biol Proced Online. 2021 Jan 20;23(1):4
pubmed: 33472576
Crit Care Med. 2013 Feb;41(2):472-80
pubmed: 23263578
Crit Care Med. 2006 Jun;34(6):1647-53
pubmed: 16625129
Crit Care. 2020 Aug 28;24(1):529
pubmed: 32859264
N Engl J Med. 2013 Jun 6;368(23):2159-68
pubmed: 23688302
Ann Intensive Care. 2020 Jul 16;10(1):95
pubmed: 32676824
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Eur Respir J. 2020 May 21;55(5):
pubmed: 32341111
J Surg Res. 1979 May;26(5):504-12
pubmed: 374880
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Chest. 2020 Jul;158(1):195-205
pubmed: 32224074
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Crit Care Med. 2008 Jan;36(1):69-73
pubmed: 18090369
N Engl J Med. 2018 May 24;378(21):1965-1975
pubmed: 29791822
Chest. 2003 Nov;124(5):1900-8
pubmed: 14605066
Intensive Care Med. 2020 Jun;46(6):1099-1102
pubmed: 32291463
Intensive Care Med. 2020 Dec;46(12):2187-2196
pubmed: 33089348
Crit Care. 2011 Aug 27;15(4):R204
pubmed: 21871112
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Am J Respir Crit Care Med. 2020 Jul 15;202(2):287-290
pubmed: 32479162
Ann Intensive Care. 2014 Aug 13;4:27
pubmed: 25593743
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Br J Anaesth. 2005 Jun;94(6):748-55
pubmed: 15790674
Crit Care Med. 2013 Sep;41(9):2144-50
pubmed: 23760152
Am J Respir Crit Care Med. 2017 May 1;195(9):1253-1263
pubmed: 28459336
Eur Heart J. 2020 May 14;41(19):1821-1829
pubmed: 32383763
J Appl Physiol Respir Environ Exerc Physiol. 1982 Dec;53(6):1614-9
pubmed: 6759494
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Curr Opin Crit Care. 2019 Jun;25(3):273-279
pubmed: 30883386
Crit Care Med. 2020 Jun;48(6):e440-e469
pubmed: 32224769
JAMA. 2020 Jun 9;323(22):2329-2330
pubmed: 32329799
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Intensive Care Med. 2001 Nov;27(11):1814-8
pubmed: 11810127
Intensive Care Med. 2007 Mar;33(3):448-53
pubmed: 17221189
Respir Physiol Neurobiol. 2020 Aug;279:103455
pubmed: 32437877
Chest. 2021 Mar;159(3):1182-1196
pubmed: 33217420
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Anaesth Intensive Care. 1999 Aug;27(4):357-62
pubmed: 10470388
Circulation. 2020 Jan 21;141(3):161-171
pubmed: 31587565
Ann Intensive Care. 2020 Sep 16;10:124
pubmed: 32953201
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Ann Intensive Care. 2020 May 12;10(1):55
pubmed: 32399901